American Vanguard (AVD) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 Jul, 2026Executive summary
Net sales increased 7% year-over-year to $124 million in Q1 2026, led by strong U.S. crop and specialty product growth, while international sales declined 7% due to timing issues in Brazil and India.
Gross margin improved to 31% from 26% in Q1 2025, with gross profit rising 27% to $38.4 million.
Adjusted EBITDA surged 245% to $10.3 million, driven by higher-margin product sales and operational efficiency.
Net loss narrowed to $4.1 million ($0.14 per share) from $8.5 million ($0.30 per share) in Q1 2025.
Strategic actions included manufacturing optimization, leadership changes, and a new capital structure to support growth.
Financial highlights
Net sales rose to $124 million from $116 million year-over-year, a 7% increase.
Gross margin expanded by 500 basis points to 31% year-over-year.
Adjusted EBITDA reached $10.3 million, up from $3 million, a 245% increase.
Cash at quarter-end was $71 million, up from $12 million a year ago, mainly due to refinancing.
Net debt stood at $196 million, up from $154 million, primarily due to lower customer prepayments.
Outlook and guidance
Full-year 2026 guidance reaffirmed: sales of $530–$550 million and adjusted EBITDA of $44–$48 million.
Targeting over $600 million in annualized revenue by 2028, with a long-term goal of 15% EBITDA margins and a net leverage ratio of 3.0x.
Manufacturing optimization expected to yield at least $4 million in annualized savings.
Focused on double-digit EBITDA margins in the near term and reducing net debt over the next two years.
Net working capital targeted at approximately 30% of sales.
Latest events from American Vanguard
- Directors elected, auditor ratified, and ambitious growth targets set amid market headwinds.AVD
AGM 20263 Jun 2026 - 2025 margins and EBITDA held steady despite lower sales; 2026 targets growth and improved profitability.AVD
Q4 20253 May 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance focus.AVD
Proxy filing23 Apr 2026 - Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 20242 Feb 2026 - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 202415 Jan 2026 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025 - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 202424 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing2 Dec 2025 - Adjusted EBITDA up 350%, gross margin 29%, and net loss narrowed on strong U.S. crop sales.AVD
Q3 202517 Nov 2025